ATX
0.205
210.6%
ASR
0.001
-50%
AR9
0.22
161.9%
CLG
0.023
-45.2%
IFG
0.011
120%
BCB
0.18
-44.6%
NHE
0.019
72.7%
AMI
0.205
-33.9%
NPM
0.019
72.7%
FCT
0.01
-33.3%
PV1
0.015
66.7%
RDN
0.004
-33.3%
JAV
0.003
50%
SRJ
0.004
-33.3%
PVT
0.009
50%
ICE
0.058
-31%
VR8
0.021
50%
DRE
0.009
-30.8%
SRL
0.73
47.5%
AON
0.005
-28.6%
FMR
0.3
46.3%
RPG
0.044
-26.7%
AHN
0.007
40%
FHS
0.003
-25%
AM5
0.007
40%
LKY
0.062
-22.5%
FDR
0.091
40%
AUG
0.021
-22.2%
EUR
0.061
38.6%
IR1
0.105
-22.2%
VMT
0.085
37.1%
MML
0.021
-22.2%
EVR
0.008
33.3%
ACM
0.06
-22.1%
LU7
0.008
33.3%
CC9
0.054
-21.7%
NAE
0.004
33.3%
JNS
0.15
-21.1%
SIS
0.004
33.3%
WTM
0.26
-20.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759